當前位置：   首頁 > 需求大廳

 >  特色服務 

1.Myopia Control with Bifocal Contact Lenses:?A Randomized Clinical Trial 2.The Role of Atropine Eye Drops in Myopia Control 4. Myopia Control: A Review 7. Efficacy of 1%?atropine?eye drops in retarding progressive axial myopia in Indian eyes 8.Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia 9.Current approaches to myopia control 10.Atropine?for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines 13. Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. 18. The treatment of myopia with?atropine?and bifocals. A long-term prospective study 19. Inhibitory effects of apomorphine and?atropine?and their combination on myopia in chicks 20. The penetration and distribution of topical?atropine?in animal ocular tissues. 21. Treatment outcomes of?myopic?anisometropia with 1%?atropine: a pilot study 23. Does?atropine?use increase intraocular pressure in?myopic?children? 24. Atropine?use for the prevention of myopia progression 25. Allergic reactions to?atropine?eye drops for retardation of progressive myopia in children. 29. Maximum?atropine?dose without clinical signs or symptoms. 31. Atropine?and bifocals can slow the progression of myopia in children. 33. Prevention of myopia onset with 0.025%?atropine?in premyopic children 35. The long-term results of using low-concentration?atropine?eye drops for controlling myopia progression in schoolchildren. 37. Prevention of myopia progression with 0.05%?atropine?solution.   [更多]

根據已知企業名稱（寫法不規范） 去CFDA http://app1.sfda.gov.cn/datasearchcnda/face3/base.jsp?tableId=25&tableName=TABLE25&title=%B9%FA%B2%FA%D2%A9%C6%B7&bcId=152904713761213296322795806604 或 藥智數據https://db.yaozh.com/pijian 查找對應的規范企業名稱 無法確認的需備注好原因 規范數據按照0.05元/條（10000條500元） 備注數據按照0.01元/條（10000條100元） 準確率要求98%。   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,”?International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010.?View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,”?American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011.?View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo?release of ciprofloxacin from ophthalmic formulations,”?International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011.?View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德國藥典   [更多]

1.Arzneimittel Forschung/Drug research 1986 36(2)，p291-303. 2.The use of antithrombotic drugs in artery disease 3. Jonassen IB, Havelund S, Ribel U, et al. Insulin Degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer ormation [J]. Diabetes, 2010, 59(Suppll): All(39-OR). 4.Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics [abstract no. 2349-PO]. Diabetes. 2011;60 Suppl:A624. 5.Technology Reports of the Osaka University, , vol. 7, p. 177,182。   [更多]

1、Drugs Fut 1989, 14(9): 875 ISSN 0377-8282 Copyright Clarivate Analytics CCC: 0377-8282 DOI: 10.1358/dof.1989.014.09.103408 2、Dionne, G. (BioChem Pharma Inc.); 1,3-Oxathiolane nucleoside analogues. EP 0526253; JP 1995500317; US 5538975; WO 9303027 . 3、Hoshi, A.; Casta?er, J.; Capecitabine. Drugs Fut 1996, 21, 4, 358 4、Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1997, vol. 36, # 9, p. 816 - 818 5、DETERMINATION OF CLENBUTEROL HYDROCHLORIDE BY SEQUENTIAL INJECTION ANALYSIS COUPLED WITH CHEMILUMINESCENCE DETECTION 6、[Bioanalytic examination and pharmacokinetics of captopril. Bioequivalence studies of different captopril-containing Tensiomin preparations]. 7、Agrati A. M., De Bartolo G., Palmieri G., Minerva Med., 83, 533-536(1992) 8、Dawes J., Hodson B. A., Pepper D. S., Thromb. Haemost, 62, 945-949(1989) 9、with mercury(II) diacetate,trifluoroacetic acid . Acta Chimica Hungarica 1986 vol.122 3-4 p261-272   [更多]

①從任務主手中獲取指定年報數量的年報文件（PDF） ②將年報中“利潤或合并利潤”、“研發或研發投入”、“行業產品地區收入”、“治療領域”、“產銷量”、“產品研發投入明細”等數據填入相應表格中（任務主提供填寫模板） ③要求仔細認真，有責任心。 ④價格2.5元/份年報預計252份，一人84份（210元），3人共計630元。 ⑤若審核發現有錯填、漏填，以每漏填，錯填一個數據1元計量扣除賞金 ⑥以前合作做過類似項目的優先考慮，如有感興趣的威客可聯系參與。   [更多]

USP39的Calcium Gluconate和Calcium Gluconate Injection標準，要求翻譯為中文   [更多]

1.論批生產記錄設計的有效性對產品質量追溯的影響——以公司內膠囊及片劑產品批生產記錄為例 2.Federal Health bulletin 4（1961）12:189 需要這個文獻 3.Morton RF, et al. Studies on the absorption, diffusion, and excretion of cycloserine. Antibiot Annu 1955-56; 3: 169-72. 4.Acta Gastroenterol Belg.1969,32（10）：771-777 A NEW ANTISPASMODIC DRUG IN THE TREATMENT OF BILIARY AND INTESTINAL DISCASCS:A CLINICAL TEST. 5.a process for preparing (S)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one https://priorart.ip.com/IPCOM/000238343   [更多]

簡介：藥智人才是最專業的醫藥產業招聘平臺，與許多醫藥行業的知名企業都有合作，職位種類豐富，崗位更專業~ 賺取賞金規則（活動時間：5月13日-5月17日）： 1.免費注冊/登錄藥智人才（https://job.yaozh.com/），上傳簡歷： 簡歷完善度≥80 可獲得50元賞金； 2.簡歷完成后，并截圖藥智人才簡歷板塊的完善度提交審核，并且備注藥智人才的用戶名/注冊手機信息； 3.審核通過后，賞金會在3個工作日內審核并發放，如提交后有刪除簡歷的行為，視為作弊處理，對應賞金將會被凍結不予提現。 4.特別福利：簡歷完善后既有機會直接內推給名企噢~ 溫馨提示： 1.如果疑問可以聯系客服QQ：3413833812 2.一經發現求職者在上傳簡歷期間有作弊等行為，藥智人才將取消其賞金并凍結該筆提現。 3.在法律允許的范圍內，本活動一切解釋權歸藥智人才 下期活動預告 活動日期：5月20-5月24日 賞金金額：更多賺取賞金細則5月20日揭曉噢~   [更多]

1.丙氨酰谷氨酰胺及其注射液的研究開發 2.A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study). Cimminiello C, Arpaia G, Polo Friz H, Boracchi P, Marano G, Spezzigu G, Visonà A. Vasa. 2015 Sep;44(5):371-9. doi: 10.1024/0301-1526/a000456. 3.2013 International Conference on Materials Engineering, ICMEN 2013 4.Orientation of substitution in the aromatic series. XVIII. Sulfonation of phenol by chlorosulfonic acid in solvents 5.Mechanism of reaction of chlorosulfonic acid with some aromatic compounds 6.Arzneimittelforschung. 1982;32(3):248-51. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. 7.Oral treatment with the Crataegus special extract WS 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension   [更多]